| DC72917 |
BDM71339 |
BDM71339 is the first small molecule inhibitor of mycobacterial transcriptional regulator EthR, boosts ten times the activity of ethionamide in TB-infected macrophages at low nanomolar concentrations (EC50=72 nM) in vitro. |
|
| DC72918 |
BDM88855 hydrochloride |
BDM88855 Hcl is a novel allosteric efflux-pump inhibitor that potentiate antibiotic activity in E. coli through inhibition of its primary RND transporter, AcrAB-TolC. |
|
| DC72919 |
BDM91288 |
BDM91288 is a pyridylpiperazine-based AcrB efflux pump inhibitor, potentiate the activity of a panel of antibiotics against K. pneumoniae. |
|
| DC72920 |
BFA1 |
BFA1 is a specific small-molecule activator of Burkholderia FixLJ signaling pathway, inhibit the virulence of multiple pathogenic Burkholderia species. |
|
| DC72921 |
COE2-2hexyl |
COE2-2hexyl is a broad-spectrum antibacterial conjugated oligoelectrolyte (COE), does not evoke bacterial resistance, inhibits methicillin-resistant S. aureus (MRSA, MT3302) with MIC of 1 ug/mL. |
|
| DC72922 |
Cresomycin |
Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides. |
|
| DC72923 |
CUO246 |
CUO246 (CUO-246) is a potent, selective bacterial DNA gyrase/topoisomerase IV inhibitor, CUO246 is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens. |
|
| DC72924 |
D66 |
D66 is a specific small molecule that disrupts S. Typhimurium membrane voltage without cell lysis, prevents S. Typhimurium survival in macrophages (IC50=6.0 uM) and inhibits bacterial growth under conditions that compromise the cell envelope. |
|
| DC72925 |
DS01750413 |
DS01750413 is a novel FtsZ inhibitor and new derivative of PC190723 (Cat. PC-47012), inhibits S. aureus FtsZ protein with IC50 of 2 mg/L, has an IC50 of 0.03 mg/L in cell elongation assay of B. subtilis. |
|
| DC72926 |
EPM35 |
EPM35 (Efflux pump modulator 35) is a small molecule that bind AcrB (KD=0.29 uM), inhibit AcrAB-TolC and modulates bacterial efflux pump activity, reduces bacterial intracellular load. |
|
| DC72927 |
GSK030 |
GSK030 (GSK3212030A) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites. |
|
| DC72928 |
GSK147 |
GSK147 (GSK-147) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=40 nM). |
|
| DC72929 |
GSK692 |
GSK692 (GSK-692) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=10 nM). |
|
| DC72930 |
HR3744 |
HR3744 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 10 uM in saeP1 promoter assays, reduces expression of hla and other virulence factors. |
|
| DC72931 |
HSGN-189 |
HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL. |
|
| DC72932 |
IITR06144 |
IITR06144 is a novel nitrofuran and exhibits broad-spectrum bactericidal activity against most MDR bacteria (MIC, 0.5 mg/mL). |
|
| DC72933 |
JBD1 |
JBD1 is a small molecule compound that strongly inhibits biofilm formation of S. aureus, including methicillin-resistant strains, induces biofilm inhibition and metabolic remodeling through respiratory activation. |
|
| DC72934 |
JMV-7061 |
JMV7061 (JMV-7061) is a novel potent, selective bacterial metallo-β-lactamase (MBL) inhibitor, shows submicromolar activities against VIM-type enzymes and strong NDM-1 inhibition (Ki=10-30 nM). |
|
| DC72935 |
JSF-2414
Featured
|
JSF-2414 (JSF2414) is a potent, small molecule GyrB/ParE dual binding inhibitor, simultaneously binds to ATP binding regions of DNA gyrase (GyrB) and topoisomerase (ParE) and displays potent in vitro activity against strains of MRSA, VRSA and VISA. |
|
| DC72936 |
JSF-2659 |
JSF-2659 is the orally bioavailable, phosphate prodrug of JSF-2414, JSF-2659 (100 and 1 g/kg, p.o.) is highly efficacious in reducing microbial burdens in animal models of Neisseria gonorrhoeae vaginal infection as well as VRSA and C. difficile-induced co |
|
| DC72937 |
JSF-3269 |
JSF-3269 is a small molecule antibacterial inhibitor against Enterococcus faecium with MIC of 1.9-3.8 uM and minimal bactericidal concentration (MBC) of 7.7-15 uM. |
|
| DC72938 |
JSF-3285 |
JSF-3285 (JSF3285) is a potent small molecule inhibitor of the M. tuberculosis β-ketoacyl synthase KasA with Kd of 70.7 nM in MST assays, shows activity against H37Rv strain with MIC 0.2 uM. |
|
| DC72939 |
KKL-55 |
KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity. |
|
| DC72940 |
KSK67 |
KSK67 is a potent small molecule inhibitor of bacterial transcriptional activator PrfA with IC50 of 67 nM, reduces virulence factor expression in L. monocytogene. |
|
| DC72941 |
LPC-233 |
LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities. |
|
| DC72942 |
MD-124 |
MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics. |
|
| DC72943 |
MMV1091186 |
MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM. |
|
| DC72944 |
MMV652103 |
MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively. |
|
| DC72945 |
MSU-43085 |
MSU-43085 is a potent, orally bioavailable inhibitor of Mycobacterium tuberculosis (Mtb, EC50=120 nM) and M. abscessus survival, targets MmpL3. |
|
| DC72946 |
ND-011992 |
ND-011992 is a cytochrome bd oxidase (Cyt-bd) inhibitor, inhibits Mycobacterium tuberculosis respiratory complex I with IC50 of 0.12 uM, targets respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases. |
|
